Genelux announces $20m public offering to fund corporate purposes.

Genelux Corporation has priced an underwritten public offering of 6.67 million shares of common stock at $3.00 per share, raising approximately $20.0 million. The net proceeds will be used for general corporate purposes, including research and development, clinical trial expenses, capital expenditures, and working capital.